Utility of Genomic Profiling Use for Targeted Therapy in a Phase I Setting Reveals that ESCAT I/II Actionable Targets are Associated with Improved Outcomes By Ogkologos - May 6, 2025 807 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CoPPO study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Cetuximab No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies MOST POPULAR Study Identifies a Potential Cause of Immunotherapy’s Heart-Related Side Effects December 22, 2022 NHL Player Carey Price Surprises 11-Year-Old Boy Who Just Lost Mom... June 24, 2019 FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma August 22, 2025 More Than 25 Additional Years Needed to Slow an Increasing Incidence... September 8, 2021 Load more HOT NEWS 41-Year-Old Wrinkled Woman Who Ages 8 Times Faster Than Normal Is... New Blood Test Can Screen For Over 50 Cancers Geriatric Assessment Intervention Reduces Patient-Reported Symptomatic Toxicities in Older Patients with... Help Desk for Oncologists Treating People with a Rare Leukemia Pays...
